Olema Pharmaceuticals inc (NAS:OLMA)
$ 11.54 -1.18 (-9.28%) Market Cap: 660.85 Mil Enterprise Value: 490.71 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 38/100

G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel Transcript

Mar 07, 2023 / 03:30PM GMT
Release Date Price: $3.77 (-4.56%)
Unidentified Analyst

Okay. I think we'll get started. Welcome back to the Cowen Healthcare Conference. Really happy to have -- next up with a panel discussion of various development programs companies in the breast and lung cancer space. And over to my side here, we have Jack Bailey from G1 Therapeutics; Filip Janku, the CMO from Monte Rosa; Eric Poma, CEO of Molecular Templates; Shane Kovacs, the COO and CFO of Olema Oncology; as well as Alan Auerbach, CEO of Puma.

Maybe to start off, we're going to start the conversation with some general topics that hopefully are a bit interactive between the various company representatives. And then we will dive into some company-specific questions. I think Joe is going to lead off with one of the general questions.

Questions & Answers

Unidentified Analyst

Thanks, Mark. And just a reminder for the audience, if you do have any questions for our panelists, feel free to e-mail us at [email protected], and we can try and get those into the discussion. But maybe just to start off, we've seen a couple of instances over the past

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot